Solar urticaria treated successfully with intravenous high‐dose immunoglobulin: a case report

Correia, Isabel; Silva, João Maia; Filipe, Paulo; Gomes, Manuel Ferreira

doi:10.1111/j.1600-0781.2008.00386.x

Cited by 21 publications

(13 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most squamous cell carcinomas and basal 314 cell carcinomas are found on the sun-exposed body sites [12] . Furthermore, many dermatoses, such as solar urticaria, actinic dermatitis, rosacea and lupus erythematosus, are induced or exacerbated by sun exposure [13][14][15] . Finally, photo-aging is another common clinical problem induced by sun exposure.…”

Section: Introductionmentioning

confidence: 99%

Sun-Induced Changes in Stratum Corneum Function Are Gender and Dose Dependent in a Chinese Population

Liu

Fluhr

Shu-min

et al. 2010

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Previous studies have demonstrated that UVB radiation changes the epidermal permeability barrier and stratum corneum (SC) hydration. It is well known that sun exposure causes erythema, sunburn and melanoma. However, whether daily sun exposure alters SC integrity and epidermal permeability barrier function is largely unknown, especially in Chinese subjects. In the present study, we assess the SC integrity, SC hydration and epidermal permeability barrier function following various doses of sun exposure. A total of 258 subjects (124 males and 134 females) aged 18–50 years were enrolled. A multifunctional skin physiology monitor (Courage & Khazaka MPA5) was used to measure SC hydration and transepidermal water loss (TEWL) on the forearms. In males, basal TEWL was higher with higher doses of sun exposure than with lower doses and control, whereas in females, basal TEWL was higher with lower doses of sun exposure than with higher doses and control. In the group with higher doses of sun exposure, TEWL in females was significantly lower than that in males. The barrier recovery was faster in females than in males in both control and lower-dose groups. In both males and females, barrier recovery was delayed with higher doses of sun exposure. In males, sun exposure did not alter SC hydration, while in females SC hydration was lower with lower doses of sun exposure as compared with control and higher doses of sun exposure. These results demonstrated that sun-induced changes in SC function and SC hydration vary with gender and the extent of sun exposure.

show abstract

Section: Introductionmentioning

confidence: 99%

Sun-Induced Changes in Stratum Corneum Function Are Gender and Dose Dependent in a Chinese Population

Liu

Fluhr

Shu-min

et al. 2010

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…One case of severe solar urticaria remitted completely following a single infusion of IVIG administered in the dose of 2g/Kg [50]. Correia et al and Darras et al also reported on remission of severe solar urticaria in single patients following high dose IVIG infusion [51,52]. While the poor response seen in the one report by Llamas-Velasco et al, may have been due to differences in product or dosage protocol, it is also quite possible that solar urticaria is a heterogeneous disease, with Alters cellular recruitment [37,43] Limits complement activation and dampens complement-mediated vascular and tissue injury [37] Inhibits inflammatory cytokines and induces inhibitory cytokines By altering Th1/2 or Th17 maturation as well as modulating glucocorticoid receptors or Fcgamma receptors on T cells and inflammatory cells [34,42,44,45] or by inhibiting T cell activation [5,37] Decreased adhesion to endothelial cells [43] Adaptive Immunity…”

Section: Efficacy Of Ivig In Urticarial Syndromesmentioning

confidence: 89%

“…IVIG has been used in solar urticaria [22,23,[49][50][51][52]. Solar urticaria is characterized by development of urticarial eruption within a few minutes of exposure to ultraviolet radiation.…”

Section: Efficacy Of Ivig In Urticarial Syndromesmentioning

confidence: 99%

Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review

Watkins¹,

Peiris²,

Saleh³

et al. 2012

IADT

View full text Add to dashboard Cite

Urticaria can be a chronic and debilitating affliction and is a relatively common disorder affecting between 10- 20% of the population. Common causes include reactions to medication, food allergen, physical stimuli and venoms. Urticaria can be acute or chronic. Chronic urticaria lasts for more than 6 weeks and is commonly difficult to treat. The use of immunosuppressive agents for this disorder when antihistamines fail can result in significant morbidity. Recent advances in the pathogenesis, etiology, diagnosis and management of chronic urticaria have led to new paradigms in treatment of this disorder. Cyclosporine is often the most effective but has some unique adverse effects that may prevent it from being used in some patients. The use of intravenous immunoglobulin (IVIG) has proven effective in a variety of reports and we will review the mechanisms likely involved in the successful control of urticarial symptoms by immunomodulating therapy using IVIG. In this review, we will discuss mechanisms and pathogenesis of urticaria and the specific role of intravenous immunoglobulin (IVIG) in this disorder, especially in refractory or steroid-dependent cases.

show abstract

“…First‐line treatment with H1‐blockade and sun blockers may be enough for some patients, but induction of tolerance with an artificial UV source is sometimes recommended, in more severe cases (1). Other treatment options such as plasma exchange or photopheresis are based on the suspected existence of a circulating factor (2).…”

Section: Discussionmentioning

confidence: 99%

Solar urticaria unresponsive to intravenous immunoglobulins

Llamas‐Velasco

Argila

Eguren

et al. 2011

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

The treatment of solar urticaria (SU) can be difficult. Only a few cases of SU have been treated with intravenous immunoglobulins (IVIg) (as monotherapy or combined with phototherapy), with reported fast and durable increase of solar exposure tolerance. A 61-year-old female with severe UVB- and UVA-induced SU and a 62-year-old female with severe UVA and visible light-induced SU were both treated with a single course of IVIg (total dose of 2 g/kg), infused over 3 days. Phototest, performed 3 months after the treatment, showed only a slight minimal urticating dose improvement, and both patients reported just a moderate and 'transient' subjective improvement. Our patient's poorer response, compared with previous reports, may be due to differences in IVIg's treatment schedules, which are reviewed.

show abstract

Solar urticaria treated successfully with intravenous high‐dose immunoglobulin: a case report

Cited by 21 publications

References 3 publications

Sun-Induced Changes in Stratum Corneum Function Are Gender and Dose Dependent in a Chinese Population

Sun-Induced Changes in Stratum Corneum Function Are Gender and Dose Dependent in a Chinese Population

Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review

Solar urticaria unresponsive to intravenous immunoglobulins

Contact Info

Product

Resources

About